NCT04410575Completed
Mental Health Assessment and Prescribing by Alberta Pharmacists
Mental Health Assessment and Prescribing by Alberta Pharmacists (MAP-AP)
Source: ClinicalTrials.gov · Last updated 4 Jul 2025
Brief summary (registry, in English)
This is a clinical trial evaluating the experimental intervention of enhanced pharmacist care by pharmacists with additional prescribing authorization (APA) in Alberta, for patients newly diagnosed with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 13 (actual)
- First submitted
- 21 May 2020
- Start date
- 22 Mar 2023
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- University of Alberta
- Diseases
- Depression
- NCT number
- NCT04410575
What you commit to
- Study type: Interventional
- Participants enrolled: 13
- From 22 Mar 2023 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients diagnosed with concurrent ADHD, bipolar disorder, schizophrenia and schizoaffective disorder
Other illness
- History of and/or current substance abuse, intoxication, addiction or withdrawal
- Patients diagnosed with comorbid anxiety disorders other than GAD, including: panic -disorder, agoraphobia, specific phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder
- Patients diagnosed with comorbid depressive disorder other than MDD, including: depressive disorder due to another medical condition (e.g. hypothyroidism, MS, OSA, -Parkinsons, stroke, TBI, Vitamin B12 insufficiency, Huntington disease, adrenal insufficiency, mononucleosis, systemic lupus erythematosus), adjustment disorder with depressed mood
Other
- Pregnancy
- Non-Alberta residents
- Unwilling or unable to participate in regular follow-up visits
- Unwilling to participate/sign consent form
- ≥2 suicide attempts per year
- Severe, psychotic, and catatonic depression
Who the study is looking for
- Adults (≥ 18 years of age) newly diagnosed with MDD and/or GAD, including:
- Patients starting on medications for the management of adults with MDD
- Patients starting on medications for the management of GAD
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.